[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100457217":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":42,"centralContacts":47,"locations":56,"responsibleParty":72,"collaborators":75,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":27,"eligibilityCriteria":84,"healthyVolunteers":85,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":27,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":58,"whyStopped":27,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"University of Copenhagen","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Post-exercise insulin sensitivity following placebo administration","PLACEBO_COMPARATOR","Young healthy males will ingest placebo (blinded) and perform a single bout of knee-extensor exercise and insulin action is investigated 4 hours after cessation of exercise. Insulin action towards muscle glucose uptake and protein synthesis will be investigated during a 120 min euglycemic hyperinsulinemic clamp.",[13,14,15],"Other: Exercise","Procedure: Insulin infusion","Drug: Placebo",{"label":17,"type":18,"description":19,"interventionNames":20},"Post-exercise insulin sensitivity following Rapamycin administration","EXPERIMENTAL","Young healthy males will ingest Rapamycin (blinded) and perform a single bout of knee-extensor exercise and insulin action is investigated 4 hours after cessation of exercise. Insulin action towards muscle glucose uptake and protein synthesis will be investigated during a 120 min euglycemic hyperinsulinemic clamp.",[13,14,21],"Drug: Rapamycin",[23,28,33,38],{"type":6,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"Exercise","1 hour of one-legged knee-extensor exercise followed by 4 hours of rest",[17,9],null,{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":27},"PROCEDURE","Insulin infusion","2 hours of Euglycemic Hyperinsulinemic Clamp",[17,9],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":27},"DRUG","Placebo","Administration of 800 mg of calcium tablets",[9],{"type":34,"name":39,"description":40,"armGroupLabels":41,"otherNames":27},"Rapamycin","Administration of 16 mg of Rapamycin tablets",[17],[43],{"name":44,"affiliation":45,"role":46},"Jørgen FP Wojtaszewski, Professor","Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Denmark","PRINCIPAL_INVESTIGATOR",[48,52],{"name":44,"role":49,"phone":50,"phoneExt":27,"email":51},"CONTACT","+4535321625","jw@nexs.ku.dk",{"name":53,"role":49,"phone":54,"phoneExt":27,"email":55},"Magnus R Larsen, MSc","+4540186274","Marl@nexs.ku.dk",[57],{"facility":5,"status":58,"city":59,"state":27,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"RECRUITING","Copenhagen","2100","Denmark","DK",{"type":64,"coordinates":65},"Point",[66,67],12.56553,55.67594,{"lat":67,"lon":66},[70],{"name":44,"role":49,"phone":50,"phoneExt":27,"email":71},"Jw@nexs.ku.dk",{"type":46,"investigatorFullName":73,"investigatorTitle":74,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"Professor Jorgen FP Wojtaszewski","Professor",[76],{"name":77,"class":6},"Danish Diabetes Academy","100457217","mtor-as-mediator-of-insulin-sensitivity-study-100457217",false,"NCT05233722","mTOR as Mediator of Insulin Sensitivity Study","Mechanistic Target of Rapamycin (mTOR) as Mediator of Exercise-induced Insulin Sensitivity Study","Inclusion Criteria:\n\n* Healthy persons (no known disease) without diabetes in the family\n* No use of medications\n* Non-smokers\n* Men\n* Age 22-35 years\n* Physical activity level (VO2peak) between 30-50 mL O2\u002Fmin\u002Fkg\n* BMI between 18.0 and 25.0\n\nExclusion Criteria:\n\n* Women\n* Physical activity (e.g., running, cycling, fitness, etc.) above 6 hours a week.\n* Persons who show signs of metabolic diseases, hematologic diseases, reduced liver function, human immunodeficiency virus (HIV), hepatitis, thyroid diseases or other signs of disease that may affect the outcome of the study or the study subject's wellbeing will be excluded.\n* Acute sickness less than 2 weeks prior to study start.\n* If disease appears or is identified and\u002For a need for medication arises after inclusion but before initiation of the study.\n\nDisease during conclusion of the study",true,"MALE","22 Years","35 Years",{"count":90,"type":91},10,"ESTIMATED","INTERVENTIONAL",[94],"NA","The study investigates the role of mTOR in mediating enhancement of muscle insulin sensitivity following a single bout of exercise.\n\nThis will be investigated in young healthy male subjects by administering the pharmacological mTOR inhibitor Rapamycin in a crossover blinded experimental setup known to enhance muscle insulin sensitivity following one-legged knee-extensor exercise.",[97],"Insulin Sensitivity",[24,99,100,101,102],"Muscle insulin Sensitivity","Muscle Glucose uptake","Muscle protein synthesis","mTOR","2024-05-14",{"date":105,"type":106},"2024-05-16","ACTUAL",{"date":108,"type":106},"2022-02-10",{"date":110,"type":91},"2029-06",{"name":5,"class":6},1]